Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis.
about
Immunoregulatory molecules are master regulators of inflammation during the immune responseIndoleamine 2,3 dioxygenase in intestinal diseaseThe microbiota and inflammatory bowel disease: insights from animal modelsMeat Intake and the Dose of Vitamin B3 - Nicotinamide: Cause of the Causes of Disease Transitions, Health Divides, and Health Futures?Tryptophan catabolism restricts IFN-γ-expressing neutrophils and Clostridium difficile immunopathologyTryptophan metabolite activation of the aryl hydrocarbon receptor regulates IL-10 receptor expression on intestinal epitheliaBin1 attenuation suppresses experimental colitis by enforcing intestinal barrier function.The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists.IDO1 and IDO2 non-synonymous gene variants: correlation with crohn's disease risk and clinical phenotype.Serum analysis of tryptophan catabolism pathway: correlation with Crohn's disease activityMicroRNA-146a constrains multiple parameters of intestinal immunity and increases susceptibility to DSS colitis.Biomarkers in inflammatory bowel disease: current practices and recent advances.Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenaseLactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner.Engineering DNA nanoparticles as immunomodulatory reagents that activate regulatory T cells.Severity of DSS-induced colitis is reduced in Ido1-deficient mice with down-regulation of TLR-MyD88-NF-kB transcriptional networksModeling colitis-associated cancer with azoxymethane (AOM) and dextran sulfate sodium (DSS).Allosteric modulation of metabotropic glutamate receptor 4 activates IDO1-dependent, immunoregulatory signaling in dendritic cells.Intestinal CD103(+)CD11b(-) dendritic cells restrain colitis via IFN-γ-induced anti-inflammatory response in epithelial cells.Enhanced immunoregulation of mesenchymal stem cells by IL-10-producing type 1 regulatory T cells in collagen-induced arthritis.IDO1 metabolites activate β-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in miceIndoleamine 2,3-dioxygenase: is it an immune suppressor?Toll-like receptor 9 agonists as cancer therapeutics.Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance.Integrated stress response-altered pro-inflammatory signals in mucosal immune-related cells.Innate immune responses in the CNS: role of toll-like receptors, mechanisms, and therapeutic opportunities in multiple sclerosis.Physiologic TLR9-CpG-DNA interaction is essential for the homeostasis of the intestinal immune system.Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer.Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.Tissue metabolism and the inflammatory bowel diseases.Epithelial Histone Deacetylase 3 Instructs Intestinal Immunity by Coordinating Local Lymphocyte Activation.Local Delivery of the Toll-Like Receptor 9 Ligand CpG Downregulates Host Immune and Inflammatory Responses, Ameliorating Established Leishmania (Viannia) panamensis Chronic Infection.Inhibition of acute lethal pulmonary inflammation by the IDO-AhR pathway.Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice.Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.Impact of the Gut Microbiota on Intestinal Immunity Mediated by Tryptophan Metabolism.N-(3', 4'-dimethoxycinnamonyl) anthranilic acid alleviated experimental colitis by inhibiting autoimmune response and inducing CD4+ CD25+ regulatory T cells production.Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice.Harnessing the Induction of CD8 T-Cell Responses Through Metabolic Regulation by Pathogen-Recognition-Receptor Triggering in Antigen Presenting CellsDownregulation of Interleukin- (IL-) 17 through Enhanced Indoleamine 2,3-Dioxygenase (IDO) Induction by Curcumin: A Potential Mechanism of Tolerance towards
P2860
Q27022027-742CAA30-D22B-46AB-897C-59F13789C52EQ27025063-699314F5-FA8D-4E94-B182-A462DDEA31A4Q27027929-A557CF0D-FE69-4FEF-AEFF-33957DB8E0C8Q33642585-6EC7CBC0-5E07-4E7A-9BF7-0F7827C6B8A2Q33880455-5B7A1EBC-BE6E-4CD7-B808-FDCC4E812CEBQ33915720-71AF5E93-59BB-4D38-B47F-5D276D65F6EFQ34270337-A312044F-2186-49FE-9441-DDCDDE026892Q34553267-91D7CC7B-327D-4543-B564-D8753D3B662BQ34776749-81E5B437-1C99-4C49-B818-D7123A2B7EDFQ35605835-2F45276A-B8FB-4C20-9707-FECC82E90412Q35803149-CA2AEF83-55A5-44BA-AC69-4ADD1E296BD0Q35840853-16E780AC-2758-4CB4-80AB-4C90EE2CA7EAQ35911231-4E17CA75-68AE-4FAD-9FC3-3FFC2EDF3597Q35939274-0197CBC9-0AEE-4F52-A7BE-36B995E9CA12Q35949475-856A1681-CCD5-4046-86AF-7BD4C10CDB7BQ36323786-6D731E5A-6E67-47BC-BFD2-F73198E1A70AQ36375050-4E1561BA-F20D-45C5-95B5-0C3603EC63AEQ36482311-06EE5262-7B09-4317-BF19-1FEEAAFADA79Q36712480-D53631DB-CE85-4914-B079-6739443C256BQ36953989-F7A19AFF-73F8-49F0-BA8A-50D0165B5A26Q37042990-8D11ACD1-3089-4242-8A8E-6A877D78B3D2Q37362632-97349727-5C8C-4245-A7C4-0F1D0E42B752Q37831323-3E1E1A75-A77B-4513-BA41-8C3720D46739Q38047057-E4A98EB5-A7DC-43BD-8A7B-36C2DEB09ACEQ38067151-E3F1A6A7-C963-489D-A7F6-3673FC4A5D2AQ38118170-99D8F654-0E79-46BC-A6EB-2DB9E7709492Q38311113-A474567A-657E-48B7-9C92-C775890766A0Q38571347-D565AAFD-AE78-4789-84E5-CE89936E7910Q38947206-5BDBAE40-30BD-401E-81B9-DEB28839EFE5Q39320456-D1176FA0-038C-4368-A397-10ED3184812FQ40216623-E691A8AB-0BCF-409A-AEFF-17108E0DEC21Q40385380-4F5E5D8A-5790-4CB7-95A1-088C124D0D96Q41147895-F60E6634-FD57-42D1-AF0C-0F2B113F0106Q42089828-5D9F6A21-2D5B-4F33-9324-64BA4106C30AQ48246344-F1050E71-CB2F-4B4E-A2A2-CAE6DD37CE0CQ50223024-F500905B-361D-4D15-8B28-50EC01F03948Q51004185-75534541-4E37-4D1F-B13A-2B8F5EDD1137Q53643579-C7047B97-21F0-4817-8C71-A93F2C34B09FQ58556287-4FAA8CDE-684F-4C8E-922D-B71B6A8E4F6DQ58580659-D4F493ED-EE9F-4147-84DF-4797D1014F30
P2860
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis.
@ast
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis.
@en
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis.
@nl
type
label
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis.
@ast
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis.
@en
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis.
@nl
prefLabel
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis.
@ast
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis.
@en
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis.
@nl
P2093
P2860
P356
P1476
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis.
@en
P2093
Ellen E Bettonville
George C Prendergast
Keely G McDonald
Matthew A Ciorba
Richard Metz
William F Stenson
P2860
P304
P356
10.4049/JIMMUNOL.0900291
P407
P577
2010-02-24T00:00:00Z